BU BÖLÜM HAKKINDA
In this episode, we ask a defining question: will multi-specific therapies revolutionize how we treat complex diseases? Host Nicola Hill is joined by Dr Joe Rastrick (UCB) and Professor Raj Chovatiya (Rosalind Franklin University) to examine whether medicines engineered to target multiple pathways can be more effective and personalized than current single-target or broad-spectrum approaches.
Discover how by leveraging combinatorial biology, researchers are working on designing therapies that have more precise targeting, focusing only on the pathways driving disease, while avoiding the ones that maintain health. The episode also discusses practical barriers, from molecule complexity to immunogenicity, trial design and regulatory uncertainty.
This podcast is produced and funded by UCB. It discusses combination therapies for informational purposes only. It does not constitute medical advice. Always consult a healthcare professional regarding health matters and prescription medicines and follow the label guidelines.
Hosted on Acast. See acast.com/privacyhttps://acast.com/privacy for more information.
GL-OT-2600004 – May 2026
Hosted on Acast. See acast.com/privacy for more information.
